加载中
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
前收盘价
US$9.46
+US$0.17 · +1.83%
盘中时间采用ET。市场数据可能有所延迟。
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
日内区间
当前US$9.46
52周区间
当前US$9.46
盘中时间采用ET。市场数据可能有所延迟。
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
日内区间
当前US$9.46
52周区间
当前US$9.46
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1625.86万 USD | 1129.27万 USD | 873.5万 USD | 419.58万 USD | 12.65万 USD |
| 销售、一般及管理费用 | 1369.78万 USD | 1138.2万 USD | 740.61万 USD | 402.32万 USD | 122.55万 USD |
| 营业费用 | 2995.64万 USD | 2267.47万 USD | 1614.11万 USD | 821.89万 USD | 135.2万 USD |
| 利息收入 | 55.55万 USD | 101.74万 USD | 57.2万 USD | — | — |
| 利息支出 | — | — | — | 497 USD | 17.99万 USD |
| 折旧和摊销 | 36.45万 USD | 11.54万 USD | 5468 USD | 2135 USD | 2468 USD |
| 营业利润 | −2995.64万 USD | −2267.47万 USD | −1614.11万 USD | −821.89万 USD | −135.2万 USD |
| 净利润 | −2943.86万 USD | −2161.34万 USD | −1542.6万 USD | −822.97万 USD | −2438.39万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$23.33
上涨空间 146.62%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2498.03万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1937.2万0.20%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1458.01万0.02%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF966.72万0.01%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO510.48万0.04%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO331.27万0.02%180亿 USD0.06%US$112.66+0.50%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS241.84万0.61%3.99亿 USD0.60%US$107.24+1.40%
iShares Micro-Cap ETFIWC174.82万0.13%13.17亿 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
